Therapeutic advances in metabolic treatment are driving unprecedented capital reallocations across the pharmaceutical industry. Manufacturing capacity constraints remain the primary bottleneck to meeting global consumer demand.
Supply Chain and Manufacturing Expansion
Major drug manufacturers are dedicating substantial capital expenditures toward fill-finish facility expansions and active pharmaceutical ingredient production contracts, reordering sectoral growth trajectories.